GLP-1
Liraglutide (Victoza & Saxenda): Complete 2026 Guide
Liraglutide has been reshaping metabolic medicine since its FDA approval in 2010. Sold under the brand names Victoza (for type 2 diabetes) and Saxenda (for chronic weight management), it was the first once-daily GLP-1 receptor agonist to demonstrate cardiovascular mortality benefits in a large outcomes trial. Now, in 2026, generic